Sustained release of peptides from pharmaceutical compositions

A composition and drug technology, applied in the direction of drug devices, drug delivery, medical containers, etc., can solve problems such as discomfort and patient inconvenience, and achieve the effect of reducing volume

Inactive Publication Date: 2006-10-18
SOC DE CONSEILS DE RECH & DAPPLICATIONS SCI SAS
View PDF56 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But such continuous injection brings inconvenience and discomfort to the patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained release of peptides from pharmaceutical compositions
  • Sustained release of peptides from pharmaceutical compositions
  • Sustained release of peptides from pharmaceutical compositions

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0078] The preparation method of the present invention avoids the dissolution problems of many peptides because it is not necessary to dissolve the peptides prior to injection. Another advantage of the solid composition of the present invention is its stability. Anhydrous solid compositions avoid problems of degradation, crystallization, bulking and solidification associated with hydration sustained release formulations such as hydrogels.

[0079] The following is a method of mixing the peptide and the carrier, and filling the resulting solid pharmaceutical composition into a syringe through a trocar.

[0080] The carrier, such as sorbitol, is dissolved in a liquid excipient for manufacture, such as water or an organic solvent, and the resulting solution is mixed with the desired peptide to form a homogeneous semisolid mixture. If the final solid composition does not contain a carrier, the peptide is simply mixed with water or other liquid excipient to form a semi-solid mixtu...

Embodiment 1

[0094] Example 1: 100% SOMATULINE TM solid composition

[0095] Add 140 mg of water to the somatostatin analog SOMATULINE TM (Kinerton, Ltd., Dublin, Ireland) acetate 60 mg. Unless otherwise specified, SOMATULINE in the following columns TM In the example, SOMATULINE is used TM of acetate. The mixture was kneaded with a spatula in a 2 ml plastic syringe and added to a stainless steel syringe having a 5 mm internal diameter chamber and a 2.5 mm internal diameter extrusion tip. The mixture was extruded through a syringe under the action of a syringe pump to form filaments, which were cut into 3 cm sticks and collected on glass slides. The sticks were vacuum-dried for 24 hours, resulting in sticks with a diameter of 1.4 mm containing 10 mg of SOMATULINE TM / cm. Fit the small rod into a trocar with an inner diameter of 1.5 mm and a length of 3 cm.

Embodiment 2

[0096] Example 2: 80% SOMATULINE TM , a solid composition of 20% mannitol

[0097] Referring to the procedure of Example 1, firstly, 1 gram of mannitol (Roquette, Lestrein, France) was mixed with 9 grams of water to form a solution. Add 0.140 g of this solution to 0.060 g of SOMATULINE TM , the extruded filaments were sheared, collected on glass slides, and dried under vacuum for 24 hours. The resulting 2.9 cm sticks contained 40 mg of SOMATULINE TM (20% by weight mannitol and 80% by weight SOMATULINE TM ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention features a solid, non-particulate, sustained-release pharmaceutical composition for parenteral administration to a patient. The composition consists essentially of: (1) a soluble, gelable peptide salt, and (2) up to 30 percent by weight of a pharmaceutically acceptable, monomeric, soluble carrier, compounded into a solid cylindrical form, wherein the solid composition automatically forms a gel after interaction with the patient's bodily fluids, the gel releasing the peptide continuously within the patient over an extended period of at least three days.

Description

[0001] The present invention is a divisional application filed on August 31, 1995, the applicant number is 95195473.3, and the title of the invention is "Sustained Release of Peptides from Pharmaceutical Compositions". field of invention [0002] The present invention relates to parenteral administration of sustained release peptide compositions. Background of the invention [0003] Peptides are usually administered parenterally, such as subcutaneously, because they are often degraded in the gastrointestinal tract. [0004] Many peptide drugs (such as insulin, LHRH, and somatostatin) require continuous or repeated dosing to patients over a period of time. But such continuous injection brings inconvenience and discomfort to the patient. [0005] Sustained-release formulations release the peptide over an extended period of time without repeated injections. Solid polymeric microcapsules and matrices such as biodegradable polylactic acid have been developed. See, eg, US Paten...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61J1/00A61J1/20A61K9/06A61K9/10A61K9/16A61K9/19A61K9/20A61K9/70A61K38/00A61K38/04A61K38/09A61K38/16A61K38/22A61K38/23A61K38/25A61K38/28A61K38/29A61K38/31A61K47/00A61K47/26A61K47/36A61M5/142A61M5/315A61M31/00
CPCA61J1/2089A61J1/2096A61K9/0019A61K9/0024A61K9/06A61K9/1629A61K9/19A61K9/2018A61K9/70A61K38/09A61K38/23A61K38/25A61K38/29A61K38/31A61K47/26A61M5/14244A61M5/14248A61M5/2448A61M5/284A61M5/31505A61M5/31531A61M31/002A61M37/0069A61J1/201A61J1/2013A61J1/2086A61K9/00
Inventor R·彻里夫-奇克
Owner SOC DE CONSEILS DE RECH & DAPPLICATIONS SCI SAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap